GlassScriptPhysician profile
Melissa J Lewin
NPI 1770115289
$4,739.92
in general payments reported to CMS, 2019-2025
29 companies · $18.70 in 2025
The $18.70 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,594 · 2022: $2,142 · 2023: $899 · 2024: $86.09 · 2025: $18.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.31 | 2021-2025 | |
| Lundbeck LLC | $599.74 | 2021-2023 | Vyepti |
| Collegium Pharmaceutical, INC. | $571.77 | 2021-2024 | Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $352.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.36 | 2021-2023 | Relistor |
| Amgen INC. | $291.08 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $190.67 | 2021-2022 | |
| Allergan, INC. | $189.09 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $187.01 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.08 | 2021-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $149.11 | 2021 | |
| Almatica Pharma LLC | $138.56 | 2021-2023 | Gralise |
| Upsher-Smith Laboratories LLC | $118.27 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $73.93 | 2023 | Trudhesa |
| Pfizer INC. | $66.85 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.49 | 2022-2023 | Reyvow, Emgality |
| Redhill Biopharma INC. | $38.01 | 2021 | |
| Axsome Therapeutics, INC. | $29.41 | 2023 | Auvelity |
| Averitas Pharma INC. | $28.41 | 2023 | Qutenza |
| Eisai INC. | $25.54 | 2022 | |
| Biodelivery Sciences International, INC. | $25.06 | 2021 | |
| Medtronic, INC. | $22.02 | 2023 | Intellis Adaptivestim |
| Abbott Laboratories | $21.74 | 2024 | Proclaim |
| Jazz Pharmaceuticals INC. | $17.19 | 2021 | |
| Merck Sharp & Dohme LLC | $17.02 | 2023 | Belsomra |
| Boston Scientific Corporation | $15.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.03 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.98 | 2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $14.00 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lewin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.